Medigene AG: Participation at upcoming virtual conferences

Planegg/Martinsried (pta036/07.04.2021/22:30 UTC+2) 7 April 2021. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will participate at the following upcoming scientific conferences. Please note that all mentioned conferences will be conducted virtually due to the COVID-19 pandemic.

AACR Annual Meeting 2021, Week 1
10-15 April 2021
https://www.aacr.org/meeting/aacr-annual-meeting-2021/

18th CIMT Annual Meeting
10-12 May 2021
http://www.meeting.cimt.eu/

2nd TCR-based Therapies Summit
8-10 June 2021
https://tcr-therapies-summit.com/

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene
Dr. Gary Waanders, Dr. Anna Niedl
Phone: +49 89 2000 3333 01
e-mail: investor@medigene.com

LifeSci Advisors
Mary-Ann Chang
Phone: +44 7483 284 853
e-mail: mchang@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.com
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate